{Reference Type}: Journal Article
{Title}: Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
{Author}: Izu-Belloso R;Gainza-Apraiz I;Ortiz-Romero P;Servitje-Bedate O;Fernández de Misa-Cabrera R;Peñate Y;Hernandez-Machin B;Estrach-Panella T;Llamas-Velasco M;Yanguas-Bayona JI;Morillo-Andujar M;Acebo-Mariñas E;Perez-Gala S;Armario-Hita JC;Sanchez-Sambucety P;Ortiz-Brugues A;Eguren-Michelena C;Bielsa-Marsol I;Lopez-Pestaña A;Blanes-Martinez M;Fernandez-Guarino M;Lopez-Lerma I;
{Journal}: Actas Dermosifiliogr
{Volume}: 115
{Issue}: 6
{Year}: 2024 Jun 22
暂无{DOI}: 10.1016/j.ad.2023.12.007
{Abstract}: OBJECTIVE: Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL.
METHODS: This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals.
RESULTS: A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported.
CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.